CSL Ltd (CSL)

269.07
+0.78(+0.29%)
  • Volume:
    1,130,986
  • Bid/Ask:
    269.00/269.09
  • Day's Range:
    267.11 - 269.33

CSL Overview

Prev. Close
268.29
Day's Range
267.11 - 269.33
Revenue
13.06B
Open
268.75
52 wk Range
242 - 328.86
EPS
7.53
Volume
1,130,986
Market Cap
122.42B
Dividend (Yield)
1.35 (1.05%)
Average Vol. (3m)
839,388
P/E Ratio
35.73
Beta
0.45
1-Year Change
-17.17%
Shares Outstanding
454,974,366
Next Earnings Date
Aug 19, 2021
What is your sentiment on CSL Ltd?
or
Market is currently closed. Voting is open during market hours.

CSL Ltd News

CSL Ltd Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyNeutral

CSL Ltd Company Profile

CSL Ltd Company Profile

Employees
27000
Market
Australia

CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products.

Read More
  • Profit Annual growth of 16% from 2018, price form 2018 $200, 2019 $230, 2020 $270,  According to the FY20 result, the F21 estimate Growth of  0%--8% so 2021 estimate prices should be $270-$291. need to see the half year result, I believe it will be better than expected,  it is a good buy now.
    1
    • where Will this stock be in a few years?
      0
      • good price today around $285
        0
        • In current COVID-19 situation CSL has an enormous potential to increase their profits  from contracts with AUS gov and many other countries. it is a rare chance to monetise CSL vaccine development expertise on global scale. it is even hard to calculate the prfit increase, it is going to be huge if played well.
          0
          • Do you think this stock is a buy?
            0
            • Yes 100 procent
              0
          • what are the opinions about this stock
            0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.